In this episode, Rich firstly chats with Dr Jyoti Bajpai, an oncologist in Mumbai who prioritises providing precision symptom care for her patients, despite the 100+ patients she sees daily. They discuss Bajpai’s randomised controlled trial on scalp cooling, her discoveries on regrowth as a secondary endpoint, and the importance of treatment sequencing to reflect each individual patient’s definition of success.
Rich then speaks to Professor Masakazu Toi, a breast oncologist from the Kyoto University in Japan. We discuss his involvement in the HOPE Study – a multicenter controlled clinical trial on scalp cooling which was revolutionary in its investigation into the role of hair regrowth as well as hair retention.
3:13 – Difference in Cancer care between an Indian hospital versus an American hospital
4:53 – Why Quality of Life is just as important as Quantity of Life in cancer care
07:49 – Bajpai discusses how looking like you have Cancer in India sometimes is associated with negative stigmas
10:27 – Measuring tolerability side effects in Bajpai’s randomised controlled trial
13:32 – Bajpai stresses the importance of good cap fit and the learning curve of good protocols in clinical teamsfitting them
15:51 – Why did Bajpai look at regrowth in her clinical trial? – All about choosing between postponement, or earlier regrowth, particularly when regimens include anthracyclines
18:54 – Regrowth results from the trial and how Bajpai’s patients reacted to this
21:14 – Bajpai’s quality of life analysis which showed a significant difference between the two patient arms
25:08 – The future of scalp cooling in India – overcoming the challenges of increased chair time pre and post
infusion, and the high number of patients coming in and out of centres
26:16 – What does changing the face of cancer mean to Bajpai? That precision care is not one size fits all
29:05 – Professor Toi discusses why he became an oncologist and his personal connection to the profession. Cancer treatment and chemotherapy was still in its primitive stages of developments
31:23 – The design of the HOPE study
32:43 – Toi and Rich discuss the subjectivity of independent assessors on hair loss as the primary endpoint
34:20 – What made them choose hair regrowth as an endpoint in the study? And what did they see? Brilliant results – scalp cooling arm, three months later, 85% of patients has hair regrowth of over 50%
Dr Jyoti Bajpai MBBS, MD, DM(AIIMS), Medical Oncologist and Associate Professor, Tata Memorial Hospital, Mumbai, India
Professor Masakazu Toi M.D. Ph. D, Medical Oncologist, Kyoto University, Japan: Breast Surgery | Graduate School of Medicine and Faculty of Medicine Kyoto University (kyoto-u.ac.jp)
Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia (2020, Bajpai et al.) “Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia” – PubMed (nih.gov)
Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in Breast Cancer Patients: the HOPE study (2019, Kinoshita et al.) Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study – PubMed (nih.gov)
Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer & the risk of scalp metastases (2017, Rugo et al.) Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis (nih.gov)
In this episode, Rich firstly chats with Dr Jyoti Bajpai, an oncologist in Mumbai who prioritises providing precision symptom care for her patients, despite the 100+ patients she sees daily. They discuss Bajpai’s randomised controlled trial on scalp cooling, her discoveries on regrowth as a secondary endpoint, and the importance of treatment sequencing to reflect each individual patient’s definition of success.
Rich then speaks to Professor Masakazu Toi, a breast oncologist from the Kyoto University in Japan. We discuss his involvement in the HOPE Study – a multicenter controlled clinical trial on scalp cooling which was revolutionary in its investigation into the role of hair regrowth as well as hair retention.
In this episode, Rich firstly chats with Dr Jyoti Bajpai, an oncologist in Mumbai who prioritises providing precision symptom care for her patients, despite the 100+ patients she sees daily. They discuss Bajpai’s randomised controlled trial on scalp cooling, her discoveries on regrowth as a secondary endpoint, and the importance of treatment sequencing to reflect each individual patient’s definition of success.
Rich then speaks to Professor Masakazu Toi, a breast oncologist from the Kyoto University in Japan. We discuss his involvement in the HOPE Study – a multicenter controlled clinical trial on scalp cooling which was revolutionary in its investigation into the role of hair regrowth as well as hair retention.
3:13 – Difference in Cancer care between an Indian hospital versus an American hospital
4:53 – Why Quality of Life is just as important as Quantity of Life in cancer care
07:49 – Bajpai discusses how looking like you have Cancer in India sometimes is associated with negative stigmas
10:27 – Measuring tolerability side effects in Bajpai’s randomised controlled trial
13:32 – Bajpai stresses the importance of good cap fit and the learning curve of good protocols in clinical teamsfitting them
15:51 – Why did Bajpai look at regrowth in her clinical trial? – All about choosing between postponement, or earlier regrowth, particularly when regimens include anthracyclines
18:54 – Regrowth results from the trial and how Bajpai’s patients reacted to this
21:14 – Bajpai’s quality of life analysis which showed a significant difference between the two patient arms
25:08 – The future of scalp cooling in India – overcoming the challenges of increased chair time pre and post
infusion, and the high number of patients coming in and out of centres
26:16 – What does changing the face of cancer mean to Bajpai? That precision care is not one size fits all
29:05 – Professor Toi discusses why he became an oncologist and his personal connection to the profession. Cancer treatment and chemotherapy was still in its primitive stages of developments
31:23 – The design of the HOPE study
32:43 – Toi and Rich discuss the subjectivity of independent assessors on hair loss as the primary endpoint
34:20 – What made them choose hair regrowth as an endpoint in the study? And what did they see? Brilliant results – scalp cooling arm, three months later, 85% of patients has hair regrowth of over 50%
Dr Jyoti Bajpai MBBS, MD, DM(AIIMS), Medical Oncologist and Associate Professor, Tata Memorial Hospital, Mumbai, India
Professor Masakazu Toi M.D. Ph. D, Medical Oncologist, Kyoto University, Japan: Breast Surgery | Graduate School of Medicine and Faculty of Medicine Kyoto University (kyoto-u.ac.jp)
Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia (2020, Bajpai et al.) “Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia” – PubMed (nih.gov)
Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in Breast Cancer Patients: the HOPE study (2019, Kinoshita et al.) Efficacy of Scalp Cooling in Preventing and Recovering From Chemotherapy-Induced Alopecia in Breast Cancer Patients: The HOPE Study – PubMed (nih.gov)
Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer & the risk of scalp metastases (2017, Rugo et al.) Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis (nih.gov)
